Postes actifs de Tom Willis
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
SonoThera, Inc.
 SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Tom Willis
Anciens postes connus de Tom Willis
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Directeur/Membre du Conseil | - | 01/01/2019 |
Statistiques
Internationale
| Etats-Unis | 3 |
Opérationnelle
| Director/Board Member | 2 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Tom Willis
- Expérience
